首頁
Sorrento Therapeutics

11月 2025Sorrento Therapeutics的市場佔有率分析

COOKIE POLICY This Cookie Policy describes how explains how Sorrento Therapeutics, Inc. and its affiliates and subsidiaries (collectively, “Sorrento,” “us,” “we,” or “our”) use cookies and similar technologies in connection with the websites, applications, and portals we operate that link to this Cookie Policy (collectively, the “Site”) to provide, improve, promote, and protect the Site […]

健康 > 生物技術和製藥

域名sorrentotherapeutics.com

成立年份1989

僱員501 - 1000

年度營收$50M - $75M

Sorrento Therapeutics

顯示Sorrento Therapeutics的主要網站流量和參與度資訊（包含公司地區）

sorrentotherapeutics.com
levenabiopharma.com

查看更多網站流量與參與度資訊

Sorrento Therapeutics截至 11月 2025 的總收入為 50M - 75M

Sorrento Therapeutics 熱門網域產生的總收入

Sorrento Therapeutics 熱門網域 3 年內的總收入

Sorrento Therapeutics 熱門網域的總收入

sorrentotherapeutics.com50M - 75M

levenabiopharma.com5M - 10M

透過銷售情報查看更多內容

Sorrento Therapeutics的熱門網域總造訪量

了解Sorrento Therapeutics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

sorrentotherapeutics.com710

levenabiopharma.com288

透過銷售情報查看更多內容

Sorrento Therapeutics的熱門網域平均造訪時長

分析Sorrento Therapeutics參與度指標。

過去 3 個月平均造訪時長

子公司細目

sorrentotherapeutics.com00:01:11

levenabiopharma.com00:01:14

透過銷售情報查看更多內容

Sorrento Therapeutics的熱門網域平均頁面瀏覽量

了解Sorrento Therapeutics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

sorrentotherapeutics.com2.17

levenabiopharma.com2.40

透過銷售情報查看更多內容

Sorrento Therapeutics按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

esperion.com公司名Esperion僱員201 - 500總部美國, 密歇根州, Ann Arbor年度營收$200M - $500M訪問總量16.8K健康 > 生物技術和製藥

使用的熱門技術Sorrento Therapeutics

这些是Sorrento Therapeutics顶级域名使用的行业网站技术

小工具 (3)

Twemoji

付費廣告 (2)

DoubleClick

內容管理系統 (2)

WordPress

轉換與分析 (2)

Google Analytics

更多技術

7

檢視所有

新聞與訊號來自Sorrento Therapeutics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Sorrento Therapeutics, Inc. has issues with securities fraud suit.The U.S. Court of Appeals for the Ninth Circuit dismissed a securities fraud suit against biopharmaceutical company Sorrento Therapeutics, concluding its claims that it found a "cure" for COVID-19, which led to a spike in stock prices, wasn't materially false or misleading.

新聞Sorrento Therapeutics, Inc. launched Offering to Dividend Short Holders on Jul 27th '23.Sorrento announces launch of voluntary Offering to Dividend Short Holders with deadline to participate by July 27, 2023.

新聞Sorrento Therapeutics, Inc. launches positive findings from a phase IIa study conducted in China on Abivertinib.Sorrento Therapeutics, Inc. (OTC: SRNEQ) has released positive findings from a phase IIa study conducted in China on Abivertinib, a dual inhibitor targeting mutant EGFR and BTK.